ArticleThe Journal of infection2022
Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals.
Abstract readLetter
In one paragraph
Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.International journal of biological sciences · 2022Pooled it
- Article
- The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection.Annals of medicine · 2023Article
- Immune interference in effectiveness of influenza and COVID-19 vaccination.Frontiers in immunology · 2023Review
- Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG.Clinical immunology communications · 2022Article
- Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination.Vaccines · 2022Article
- SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study.Journal of clinical immunology · 2022Article
- Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.Environmental research · 2022Review
- Article
- SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera.The Journal of infection · 2022Article
- Antibody titers and breakthrough infections with Omicron SARS-CoV-2.The Journal of infection · 2022Article
- Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?Molecules (Basel, Switzerland) · 2022Review
- Development and evaluation of low-volume tests to detect and characterize antibodies to SARS-CoV-2.Frontiers in immunology · 2022Article
- SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation.Frontiers in immunology · 2022Article
- The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster.Infection and drug resistance · 2022Article
- Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.Frontiers in immunology · 2022Article
- Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Sian FaustiniInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: s.e.faustini@bham.ac.uk.
Adrian ShieldsInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom. Electronic address: a.m.shields@bham.ac.uk.
Gemma BanhamInstitute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom. Electronic address: emma.banham@nhs.net.
Nadezhda WallInstitute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom. Electronic address: nadya.wall@nhs.net.
Saly Al-TaeiInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: s.al-taei@bham.ac.uk.
Chloe TannerInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: c.l.tanner@bham.ac.uk.
Zahra AhmedInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: a.zahra@bham.ac.uk.
Elena EfstathiouInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: e.efstathiou@bham.ac.uk.
Neal TownsendInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: n.j.townsend@bham.ac.uk.
Margaret GoodallInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: dm.goodall@bham.ac.uk.
Tim PlantInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: tplant.1@bham.ac.uk.
Marisol Perez-ToledoInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: m.perez-toledo@bham.ac.uk.
Aleksandra JasiulewiczInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: a.jasiulewicz@bham.ac.uk.
Ruth PriceBiomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: rk.price@ulster.ac.uk.
James McLaughlinNanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland. Electronic address: jad.mclaughlin@ulster.ac.uk.
John FarnanThe Group Surgery, 257 North Queen Street, Belfast, Northern, Ireland. Electronic address: john.farnan@doctors.org.uk.
Julie MooreBiomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: Moore-J66@ulster.ac.uk.
Louise RobertsonBiomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: lrobertson@ulster.ac.uk.
Andrew NesbitBiomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: a.nesbit@ulster.ac.uk.
Grace CurryBiomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: G.Curry@ulster.ac.uk.
Amy BlackThe Group Surgery, 257 North Queen Street, Belfast, Northern, Ireland. Electronic address: AmyBlack@doctors.org.uk.
Adam CunninghamInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: a.f.cunningham@bham.ac.uk.
Lorraine HarperUniversity Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom; Institute of Applied Health, University of Birmingham, Birmingham, United Kingdom. Electronic address: lharper@bham.ac.uk.
Tara MooreBiomedical Sciences Research Institute, Ulster University, Northern Ireland; Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland; Avellino labs USA 1505 Adams Drive Menlo Park, CA 94025 USA. Electronic address: tara.moore@ulster.ac.uk.
Mark DraysonInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: m.t.drayson@bham.ac.uk.
Alex RichterInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom. Electronic address: a.g.richter@bham.ac.uk.
Funding
Medical Research Council MR/N023706/1Medical Research Council MR/W010011/1Wellcome Trust
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19COVID-19 VaccinesAntibodies, NeutralizingAntibodies, ViralGlycoproteinsHumansSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesGlycoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibody responseChronic kidney diseaseCOVID-19Cross reactivityDeltaHaemodialysisOmicronSARS-CoV-2vaccinationVariants of Concern
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.